Halozyme Therapeutics HALO
NASDAQ HALO
$108.64 -1.76 (-1.59%)
As of: Oct 1, 2026 · 12:07 PM EDT

Halozyme Therapeutics (HALO) Receivables - Other (2019 - 2024)

Updated

Halozyme Therapeutics' Receivables - Other was $20.3 million in Q4 2024, compared with $1 million a year earlier.

Analysis

Halozyme Therapeutics (HALO) Receivables - Other (2019 - 2024) Analysis & Trends

From Q2 2019 onward, Halozyme Therapeutics has reported Receivables - Other for 11 quarters.

  • Receivables - Other shows a four-year compound annual growth rate of 30.5% (FY2020 to FY2024).
  • In earlier years, Receivables - Other was $1 million in FY2023 (-97.7%), $44.1 million in FY2022 and $7 million in FY2020.
  • The Q4 2024 figure marks the highest quarterly Receivables - Other since Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Halozyme Therapeutics 12.59 Bn 11.20 Bn 401.83 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 20.30 Mn
Dec 31, 2023 1.00 Mn
Sep 30, 2023 3.30 Mn
Jun 30, 2023 24.50 Mn
Mar 31, 2023 32.34 Mn
Sep 30, 2022 69.20 Mn
Jun 30, 2022 19.84 Mn
Mar 31, 2021 30.00 Mn
Dec 31, 2020 7.00 Mn
Sep 30, 2020 32.00 Mn
Jun 30, 2019 5.00 Mn
API Access

Halozyme Therapeutics Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=HALO&period=max&api_key=YOUR_API_KEY